NightHawk Biosciences (NYSE:NHWK) Share Price Passes Below 200-Day Moving Average of $0.68

Posted by on Oct 7th, 2023

NightHawk Biosciences, Inc. (NYSE:NHWK – Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.68 and traded as low as $0.45. NightHawk Biosciences shares last traded at $0.46, with a volume of 39,853 shares traded.

NightHawk Biosciences Price Performance

The business’s fifty day moving average is $0.60 and its 200-day moving average is $0.68. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.49 and a quick ratio of 1.49. The firm has a market cap of $12.08 million, a PE ratio of -0.23 and a beta of 0.54.

NightHawk Biosciences (NYSE:NHWK – Get Free Report) last issued its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.08). The business had revenue of $0.66 million for the quarter, compared to the consensus estimate of $0.90 million. NightHawk Biosciences had a negative return on equity of 78.84% and a negative net margin of 687.09%.

Hedge Funds Weigh In On NightHawk Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NHWK. Bank of New York Mellon Corp bought a new position in NightHawk Biosciences during the third quarter worth about $25,000. Renaissance Technologies LLC bought a new position in shares of NightHawk Biosciences in the third quarter valued at approximately $35,000. Virtu Financial LLC bought a new position in shares of NightHawk Biosciences in the fourth quarter valued at approximately $53,000. Millennium Management LLC bought a new position in shares of NightHawk Biosciences in the fourth quarter valued at approximately $54,000. Finally, Price T Rowe Associates Inc. MD bought a new position in shares of NightHawk Biosciences in the third quarter valued at approximately $57,000. Institutional investors own 21.16% of the company’s stock.

NightHawk Biosciences Company Profile

(Get Free Report)

NightHawk Biosciences, Inc, an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc and changed its name to NightHawk Biosciences, Inc in May 2022.

Read More

Receive News & Ratings for NightHawk Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NightHawk Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.